RSS Subscribe to our Nanotechnology Business News feed

BIND Biosciences, Inc. Closes $16M Series B Financing Round

BIND Biosciences, Inc., a privately held biopharmaceutical company developing 'smart' therapeutic targeted nanoparticles capable of differential delivery and controlled drug release to diseased tissue, announced today that it has secured a $16 million Series B financing.

Nov 27th, 2007

Read more